MedTrace Logo

Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

NCT01732783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 213

Last updated 2022-11-08

Study results available
· View outcomes & findings →

Summary

The primary objective was to describe the pattern of use of panitumumab (Vectibix®) in combination with chemotherapy in patients with wild-type rat sarcoma viral oncogene homolog (RAS) metastatic colorectal cancer (mCRC): as first-line treatment in combination with FOLFOX or FOLFIRI or second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).

Conditions

  • Wild-type RAS Metastatic Colorectal Cancer

Interventions

OTHER

Panitumumab + Chemotherapy

Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-10
Primary Completion
2016-11-30
Completion
2016-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01732783 on ClinicalTrials.gov